Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population‐Based Study
- 19 December 2024
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (5) , 614-624
Abstract
Objective: To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE). Design: Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014‐ongoing). Setting: Seventy‐six centres in France. Population: All pregnancies in women with SLE enrolled in the GR2 study, conceived before 1 August 2022, with available end‐of‐pregnancy data and known conception type, were included; that is, 577 spontaneous and 53 assisted pregnancies. Methods: A comparative analysis of spontaneous and assisted pregnancies was conducted. Logistic regression was used to determine if fertility treatments were independently associated with live birth prognosis, adjusting for confounders (e.g., maternal age). Kaplan–Meier analysis compared cumulative incidences of disease flares and adverse pregnancy outcomes (APOs), with confounding factors adjusted using a Cox regression model. Main Outcome Measures: Live birth, disease flares, and APOs. Results: The mean age was older (35.8 vs. 32.3 years, p < 1 × 10 −4 ), and twins were more frequent in assisted pregnancies (5/50, 10.0% vs. 20/554, 3.6%; p = 0.047). Lupus disease was clinically inactive at baseline in 51 (96.2%) assisted pregnancies (vs. n = 511, 89.6%; p = 0.15), with 35 of 45 (77.8%) having no chronic damage (vs. 448/513, 87.3%; p = 0.07). The live birth rate was similar between assisted and spontaneous pregnancies ( n = 46, 86.8% vs. n = 505, 87.5%; p = 0.83), with no statistical difference in the incidence of lupus flares and APOs. These results remained consistent after adjusting for confounding factors. Conclusions: Fertility treatments in women with mostly well‐controlled SLE did not appear to increase risks of maternal and neonatal complications, supporting current recommendations. Trial Registration ClinicalTrials.gov identifier: NCT02450396Keywords
Funding Information
- UCB
- Foundation for Research in Rheumatology
This publication has 41 references indexed in Scilit:
- First trimester preeclampsia screening and predictionAmerican Journal of Obstetrics and Gynecology, 2022
- Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysisAutoimmunity Reviews, 2022
- Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive TechnologyDrugs, 2020
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal DiseasesArthritis & Rheumatology, 2020
- Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomesJournal of Assisted Reproduction and Genetics, 2018
- Brief Report: The Euro‐Lupus Low‐Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti–Müllerian HormoneArthritis & Rheumatology, 2017
- Pregnancy and birth outcomes in couples with infertility with and without assisted reproductive technology: with an emphasis on US population-based studiesAmerican Journal of Obstetrics and Gynecology, 2017
- Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: a meta-analysis of cohort studiesFertility and Sterility, 2016
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndromeArthritis & Rheumatism, 2000